Having written about Alnylam Pharmaceuticals (NASDAQ:ALNY) in early November,
I thought I'd be done with covering the stock for a few months. Alnylam
likes to make its analysts and shareholders work, though, and the
updates from the company since then do merit further discussion.
Fortunately
for shareholders, the updates are universally positive. Revusiran
appears to be safe and while efficacy remains unknown, the company has
launched the Phase III ENDEAVOUR study. Alnylam has also reported
encouraging early-stage data on its ALN-AT3 hemophilia treatment,
started a Phase I/II study for ALN-CC5, and has seen partner The Medicines Company (NASDAQ:MDCO)
start clinical studies of ALN-PCSsc. Last and not least, the company
has shifted its strategic and research priorities a bit, with three
large areas of focus.
Much as I don't like the well-trod path on
the sell-side of "the stock has reached my price target, so I'll raise
my target", the changes in just the last month do prompt me to bump my
fair value estimate higher.
Read more here:
Alnylam Pharmaceuticals Continues To Post Encouraging Results
No comments:
Post a Comment